// App-Quantinova.ai

1196 : Safety and Efficacy of ABT-981, an Anti–Interleukin-1α/β Dual Variable Domain (DVD) Immunoglobulin, in Subjects with Knee Osteoarthritis: Results from the Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2 Trial

Researchers

Presenter

  • Roy Fleischmann

Principal Investigators

  • Henning Bliddal

  • Francisco J Blanco

  • Thomas J. Schnitzer

  • Charles Peterfy

  • Su Chen

  • Li Wang

  • Philip G. Conaghan

  • Francis Berenbaum

  • Jean-Pierre Pelletier

  • Johanne Martel-Pelletier

  • Ole Vaeterlein

  • Wei Liu

  • Gwen Levy

  • Lanju Zhang

  • Jeroen K. Medema

  • Marc C. Levesque

Medical Centers

  • Southwestern Medical Center at Dallas Metroplex Clinical Research Center, Dallas, United States

  • The Parker Institute, Bispebjerg and Frederiksberg, University of Copenhagen, Copenhagen, Denmark

  • INIBIC-Instituto de Investigaciones Biomédicas de A Coruña-Complexo Hospitalario Universitario de A Coruña, A Coruña, Spain

  • Northwestern University, Feinberg School of Medicine, Chicago, IL

  • Spire Sciences, Inc., Boca Raton, FL

  • AbbVie, Inc., North Chicago, IL

  • University Pierre & Marie Curie and Inserm, DHU i2B, APHP, Hospital Saint-Antoine, Paris, France

  • Centre Hospitalier de LUniversite de Montreal (CHUM), Montreal, QC, Canada

  • Bioclinica, Hamburg, Germany

Locations

  • United States

  • Denmark

  • Spain

  • United Kingdom

  • France

  • Canada

  • Germany

Companies

  • Spire Sciences LLC

Study Components

Therapeutic Area

  • Musculoskeletal

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Interleukin

  • ABT-981

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Controlled

  • Parallel Group

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved